CN116139267A - 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 - Google Patents
小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN116139267A CN116139267A CN202310098831.6A CN202310098831A CN116139267A CN 116139267 A CN116139267 A CN 116139267A CN 202310098831 A CN202310098831 A CN 202310098831A CN 116139267 A CN116139267 A CN 116139267A
- Authority
- CN
- China
- Prior art keywords
- mouse
- monoclonal antibody
- present
- cancer
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 title claims abstract description 35
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 title claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 title description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 31
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 31
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 31
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 21
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 21
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 230000008595 infiltration Effects 0.000 abstract description 5
- 238000001764 infiltration Methods 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种小鼠CD74单克隆抗体在制备治疗肿瘤药物中的应用；本发明小鼠CD74单克隆抗体能够改善小鼠肾癌免疫浸润以及抑制肾癌的发展，为肾癌、膀胱癌患者提供了一种潜在的靶向CD74的免疫治疗手段。
Description
技术领域
本发明涉及小鼠肿瘤治疗技术领域，具体涉及一种小鼠CD74单克隆抗体在制备治疗肿瘤药物中的应用。
背景技术
恶性肿瘤仍然是目前亟待解决的难题，给人类的生命健康带来极大地威胁，常见的治疗手段包括手术、化疗和放疗，这三种治疗方法对于改善晚期癌症病人的生命质量以及延长患者的生命时间有较大的效果，然而，对于癌症的治愈带来严峻的挑战，与此同时，给患者带来无法承受的副作用。因此，人们一直在寻找新兴的治疗手段，肿瘤免疫疗法是恶性肿瘤治疗的突破口。
有鉴于此，特提出本发明。
发明内容
本发明的目的在于提供一种小鼠CD74单克隆抗体在制备治疗肿瘤药物中的应用，本发明小鼠CD74单克隆抗体能够阻断小鼠CD74与CD276结合通路，并能够改善小鼠肾癌免疫浸润以及抑制肾癌的发展，为肾癌、膀胱癌患者提供了一种潜在的靶向CD74的免疫治疗手段。
为了实现本发明的上述目的，特采用以下技术方案：
本发明第一方面提供了一种小鼠CD74单克隆抗体在制备治疗肿瘤药物中的应用。
本发明小鼠CD74单克隆抗体能够阻断小鼠CD74与CD276结合通路，并能够改善小鼠肾癌免疫浸润以及抑制肾癌的发展，为肾癌、膀胱癌患者提供了一种潜在的靶向CD74的免疫治疗手段。
在本发明中，对肿瘤的种类不作严格限制，优选地，所述肿瘤包括肾癌和膀胱癌。
优选地，所述小鼠CD74单克隆抗体通过小鼠CD74蛋白免疫大鼠，再经分离、纯化、筛选得到。
本发明第二方面提供了一种用于治疗肿瘤的药物，所述药物包括上述小鼠CD74单克隆抗体。
本发明中对药物制剂不作严格限制，可以根据实际需要在本领域药物剂型中常规选择，优选地，所述药物剂型可以为注射剂。
优选地，所述药物还包括药学上可接受的辅料。
进一步优选地，所述辅料包括氯化钠、甘露醇、组氨酸、枸橼酸钠和注射用水。
优选地，所述肿瘤包括肾癌和膀胱癌。
与现有技术相比，本发明的有益效果至少包括：
本发明小鼠CD74单克隆抗体能够改善小鼠肾癌免疫浸润以及抑制肾癌的发展，为肾癌、膀胱癌患者提供了一种潜在的靶向CD74的免疫治疗手段。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案，下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍。在所有附图中，类似的元件或部分一般由类似的附图标记标识。附图中，各元件或部分并不一定按照实际的比例绘制。
图1为本发明实施例2中CD74单克隆抗体抑制膀胱癌的生长曲线；
图2为本发明实施例2中CD74单克隆抗体抑制肾癌的生长曲线；；
图3为本发明实施例2中CD74单克隆抗体抑制膀胱癌的拍照结果；
图4为本发明实施例2中CD74单克隆抗体抑制肾癌的拍照结果。
具体实施方式
下面将结合实施例对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚地说明本发明的技术方案，因此只作为示例，而不能以此来限制本发明的保护范围。
需要注意的是，除非另有说明，本申请使用的技术术语或者科学术语应当为本发明所属领域技术人员所理解的通常意义。
本发明实施例提供了一种小鼠CD74单克隆抗体在制备治疗肿瘤药物中的应用。
本发明小鼠CD74单克隆抗体能够改善小鼠肾癌免疫浸润以及抑制肾癌的发展，为肾癌、膀胱癌患者提供了一种潜在的靶向CD74的免疫治疗手段。
在本发明中，对肿瘤的种类不作严格限制，在一实施方式中，所述肿瘤包括肾癌和膀胱癌。
本发明实施例还提供了一种用于治疗肿瘤的药物，所述药物包括小鼠CD74单克隆抗体。
在本发明中对药物制剂不作严格限制，可以根据实际需要在本领域药物剂型中常规选择，优选地，所述药物剂型可以为注射剂。
在一实施方式中，所述药物还包括药学上可接受的辅料。
进一步地，所述辅料包括氯化钠、甘露醇、组氨酸、枸橼酸钠和注射用水。
在一实施方式中，所述肿瘤包括肾癌和膀胱癌。
以下通过具体实施例对本发明的技术方案作进一步详细说明。
实施例1
本实施例为CD74单克隆抗体的制备，具体地，通过CD74蛋白作为抗原免疫大鼠，经分离纯化、筛选得到。
实施例2
本实施例为小鼠CD74单克隆抗体体内抑制小鼠肾癌及膀胱癌研究：
1.肾癌和膀胱癌动物模型构建
用含10％胎牛血清的1640培养基培养小鼠膀胱癌细胞系MB49及小鼠肾癌细胞系Renca；
购买6-8周龄、雌性C57小鼠(18只)及Balb/c小鼠(10只)饲养于SPF环境；
于上述品系小鼠右侧腋窝皮下分别注射50万/0.1毫升MB49细胞、100万/0.1毫升Renca细胞，待肿瘤自然生长1周左右，各小鼠右侧腋窝局部触及皮下肿瘤如绿豆大小，即为小鼠皮下膀胱癌及肾癌模型构建成功。
2.给药方案及数据收集
将各品系小鼠随机各分为两组，对照组腹腔注射IgG抗体，实验组腹腔注射上述小鼠CD74单克隆抗体，剂量为5mg/kg体重，模型构建第6天开始给药并测量小鼠皮下瘤体积，给药频次为一周2次，测量频次为间隔一天一次，测量至第7-8次时处死小鼠，取出皮下瘤拍照并绘制肿瘤生长曲线。
图1、2为本发明所述CD74体内抗体在小鼠水平抑制膀胱癌、肾癌生长的曲线；
如图3、4为不同小鼠肾癌和膀胱癌大小的拍照结果；
综上，腹腔注射本发明所述CD74体内抗体，C57小鼠皮下膀胱癌及Balb/c小鼠皮下肾癌明显小于对照组，说明本发明所述的CD74体内抗体能够显著抑制膀胱癌、肾癌的进展。
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围，其均应涵盖在本发明的权利要求和说明书的范围当中。
Claims (8)
1.小鼠CD74单克隆抗体在制备治疗肿瘤药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述肿瘤包括肾癌和膀胱癌。
3.根据权利要求1所述的应用，其特征在于，所述小鼠CD74单克隆抗体通过小鼠CD74蛋白免疫大鼠，再经分离、纯化、筛选得到。
4.一种用于治疗肿瘤的药物，其特征在于，所述药物包括权利要求1所述的小鼠CD74单克隆抗体。
5.根据权利要求4所述的药物，其特征在于，所述药物剂型包括注射剂。
6.根据权利要求4或5所述的药物，其特征在于，所述药物还包括药学上可接受的辅料。
7.根据权利要求6所述的药物，其特征在于，所述辅料包括氯化钠、甘露醇、组氨酸、枸橼酸钠和注射用水。
8.根据权利要求4所述的药物，其特征在于，所述肿瘤包括肾癌和膀胱癌。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310098831.6A CN116139267A (zh) | 2023-01-28 | 2023-01-28 | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 |
| CN202410120329.5A CN118045174B (zh) | 2023-01-28 | 2024-01-29 | 一种cd74单克隆抗体作为抗肿瘤药物的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310098831.6A CN116139267A (zh) | 2023-01-28 | 2023-01-28 | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116139267A true CN116139267A (zh) | 2023-05-23 |
Family
ID=86357824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310098831.6A Pending CN116139267A (zh) | 2023-01-28 | 2023-01-28 | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 |
| CN202410120329.5A Active CN118045174B (zh) | 2023-01-28 | 2024-01-29 | 一种cd74单克隆抗体作为抗肿瘤药物的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410120329.5A Active CN118045174B (zh) | 2023-01-28 | 2024-01-29 | 一种cd74单克隆抗体作为抗肿瘤药物的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116139267A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117866909A (zh) * | 2024-01-29 | 2024-04-12 | 华中科技大学同济医学院附属同济医院 | 一种杂交瘤细胞株及其在生产cd74单克隆抗体上的应用 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100272636A1 (en) * | 1999-05-10 | 2010-10-28 | The Ohio State University | Anti-CD74 Immunoconjugates and Methods of Use |
| CN102174108A (zh) * | 2002-03-01 | 2011-09-07 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
| US20110300066A1 (en) * | 2005-04-06 | 2011-12-08 | Immunomedics, Inc. | Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases |
| US20130022541A1 (en) * | 2011-07-18 | 2013-01-24 | Immunomedics, Inc. | FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death |
| CN103207277A (zh) * | 2013-03-28 | 2013-07-17 | 中国人民解放军第二军医大学 | 一种人源性可溶型cd74蛋白的elisa检测试剂盒及检测方法 |
| CN103458930A (zh) * | 2011-02-01 | 2013-12-18 | 根马布股份公司 | 针对cd74的人抗体和抗体-药物缀合物 |
| US20140170063A1 (en) * | 2012-12-13 | 2014-06-19 | Immunomedics, Inc. | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity |
| CN104280553A (zh) * | 2014-09-22 | 2015-01-14 | 中国人民解放军第二军医大学 | 一种小鼠源性可溶型cd74蛋白的elisa检测试剂盒及检测方法 |
| CN110075295A (zh) * | 2013-07-23 | 2019-08-02 | 免疫医疗公司 | 具有cl2a接头的抗体-sn-38免疫缀合物 |
| CN114796520A (zh) * | 2016-01-27 | 2022-07-29 | 苏特罗生物制药公司 | 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
| WO2014037419A1 (en) * | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| BR112019003462A2 (pt) * | 2016-08-23 | 2019-06-25 | Glaxosmithkline Biologicals Sa | proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral |
-
2023
- 2023-01-28 CN CN202310098831.6A patent/CN116139267A/zh active Pending
-
2024
- 2024-01-29 CN CN202410120329.5A patent/CN118045174B/zh active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100272636A1 (en) * | 1999-05-10 | 2010-10-28 | The Ohio State University | Anti-CD74 Immunoconjugates and Methods of Use |
| CN102174108A (zh) * | 2002-03-01 | 2011-09-07 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
| US20110300066A1 (en) * | 2005-04-06 | 2011-12-08 | Immunomedics, Inc. | Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases |
| CN103458930A (zh) * | 2011-02-01 | 2013-12-18 | 根马布股份公司 | 针对cd74的人抗体和抗体-药物缀合物 |
| US20130022541A1 (en) * | 2011-07-18 | 2013-01-24 | Immunomedics, Inc. | FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death |
| US20140170063A1 (en) * | 2012-12-13 | 2014-06-19 | Immunomedics, Inc. | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity |
| CN103207277A (zh) * | 2013-03-28 | 2013-07-17 | 中国人民解放军第二军医大学 | 一种人源性可溶型cd74蛋白的elisa检测试剂盒及检测方法 |
| CN110075295A (zh) * | 2013-07-23 | 2019-08-02 | 免疫医疗公司 | 具有cl2a接头的抗体-sn-38免疫缀合物 |
| CN104280553A (zh) * | 2014-09-22 | 2015-01-14 | 中国人民解放军第二军医大学 | 一种小鼠源性可溶型cd74蛋白的elisa检测试剂盒及检测方法 |
| CN114796520A (zh) * | 2016-01-27 | 2022-07-29 | 苏特罗生物制药公司 | 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法 |
Non-Patent Citations (5)
| Title |
|---|
| GARY L. GRIFFITHS等: "Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate", CLINICAL CANCER RESEARCH, vol. 9, no. 17, pages 6567, XP002630671 * |
| JUN-WEI GAI等: "Expression of CD74 in bladder cancer and its suppression in association with cancer proliferation, invasion and angiogenesis in HT-1376 cells", ONCOLOGY LETTERS, vol. 15, no. 5, pages 7632 * |
| SHI-QI JI等: "Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway", UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS, vol. 32, no. 2, pages 153 * |
| 崔丽娟等: "胃腺癌中CD74蛋白的表达及其临床意义", 临床与实验病理学杂志, vol. 32, no. 11, pages 1273 - 1275 * |
| 纪世琪等: "shRNA靶向抑制CD74基因对人肾透明细胞癌细胞786-O生物学行为的影响", 现代泌尿外科杂志, vol. 21, no. 09, pages 713 - 716 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117866909A (zh) * | 2024-01-29 | 2024-04-12 | 华中科技大学同济医学院附属同济医院 | 一种杂交瘤细胞株及其在生产cd74单克隆抗体上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118045174B (zh) | 2024-10-11 |
| CN118045174A (zh) | 2024-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7316120B2 (ja) | 腫瘍性疾患のための治療 | |
| Yu et al. | 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer | |
| Yu et al. | Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy | |
| CN116139267A (zh) | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 | |
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| FI114011B (fi) | Suonensisäiseen käyttöön tarkoitetun immunoglobuliinin käyttö farmaseuttisen koostumuksen valmistamiseksi syöpäsairauksien hoitamiseksi | |
| CN114159446A (zh) | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 | |
| CN115463118A (zh) | 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途 | |
| CN117866069B (zh) | 一种碘-131标记的小分子多肽tfmp-y4及其制备方法和应用 | |
| CN117838845A (zh) | 用于治疗癌症的药物组合物 | |
| WO2015192663A1 (zh) | 重组灵芝免疫调节蛋白rLZ-8在治疗肺癌，喉癌和脑胶质瘤中的应用 | |
| CN112194723B (zh) | 一种免疫细胞在治疗癌症中应用 | |
| CN103316035A (zh) | 碳酸氢钠在制备治疗肿瘤药物中的用途 | |
| RU2524309C1 (ru) | Способ выбора тактики лечения местно-распространенного рака предстательной железы | |
| CN101224297A (zh) | 重组人血管内皮抑制素在制药中的应用 | |
| CN112076216A (zh) | 三氧化二砷在治疗胃肠道间质瘤中的应用 | |
| CN104306976A (zh) | 一种高效的肿瘤个体化免疫治疗方法及其应用 | |
| CN113975296B (zh) | 动物脾脏提取物在制备治疗阿尔兹海默症的药物中的应用 | |
| WO2024140833A1 (zh) | 药物组合及其应用 | |
| WO2022151335A2 (zh) | 一种高压氧联合免疫药物用于肿瘤治疗的方法 | |
| CN110151987B (zh) | 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途 | |
| CN111840541A (zh) | 聚肌苷酸胞苷酸联合抗cd47抗体在肿瘤治疗中的应用 | |
| CN104353061B (zh) | 血小板生成素在辐射造成肠组织损伤中的应用 | |
| CN116270580A (zh) | 巴氯芬促进三阴性乳腺癌的免疫治疗用途 | |
| Zhang et al. | Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230523 |
|
| WD01 | Invention patent application deemed withdrawn after publication |